Home Angiogenesis VDA

VDA

VDA Products

  • All (3)
  • New VDA Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1786 Verteporfin Verteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. Verteporfin is an autophagy inhibitor. Verteporfin inhibits cell proliferation and induces apoptosis.
Acta Pharm Sin B, 2024, 14(3):1222-1240
Bone Res, 2024, 12(1):12
Cancer Lett, 2024, 587:216692
S1537 Vadimezan (DMXAA) Vadimezan (DMXAA) is a vascular disrupting agents (VDA) and competitive inhibitor of DT-diaphorase with Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STING agonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-β but relatively low TNF-α expression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.
Mol Cancer, 2024, 23(1):186
Nat Commun, 2024, 15(1):1750
Cell Rep Med, 2024, 5(7):101648
S1176 Plinabulin Plinabulin is a vascular disrupting agent (VDA) against tubulin-depolymerizing with IC50 of 9.8~18 nM in tumor cells. Phase 1/2.
J Med Chem, 2022, 65(13):9159-9173
ACS Omega, 2022, 7(25):21465-21472
J Biol Chem, 2019, 294(20):8161-8170

Choose Selective VDA Inhibitors

VDASignaling Pathway

VDA信号通路图
Tags: VDA inhibitor|VDA agonist|VDA activator|VDA inducer|VDA antagonist|VDA signaling pathway|VDA assay kit